Anti-Hypertensive Drugs - Poland

Poland

In Poland, the revenue in the Anti-Hypertensive Drugs market is forecasted to reach €62.85m in 2024.
The market is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of -0.49%, leading to a market volume of €61.31m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to €11,280.00m in 2024.
Poland is witnessing a growing demand for anti-hypertensive drugs due to the increasing prevalence of hypertension among its population.

Key regions: Japan, India, Italy, Brazil, South Korea

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Poland has been on the rise in recent years.

Customer preferences: Poland's aging population is a major factor contributing to the increase in demand for Anti-Hypertensive Drugs. As people age, the risk of developing hypertension increases, leading to a higher demand for medication to manage the condition. Additionally, there has been a growing awareness of the importance of managing hypertension, leading to more people seeking treatment.

Trends in the market: In recent years, there has been a shift towards generic drugs in the Anti-Hypertensive Drugs market in Poland. This is due to the lower cost of generic drugs compared to branded drugs, which has made them more accessible to a wider population. The market has also seen an increase in the use of combination therapies, where two or more drugs are used to manage hypertension. This approach has been shown to be more effective in managing hypertension than using a single drug.

Local special circumstances: Poland has a well-developed healthcare system, which has made it easier for people to access Anti-Hypertensive Drugs. The country has a universal healthcare system, which means that all citizens have access to healthcare services, including medication. Additionally, there has been an increase in the number of pharmacies in the country, which has made it easier for people to access medication.

Underlying macroeconomic factors: Poland has a growing economy, which has led to an increase in disposable income. This has made it easier for people to afford medication, including Anti-Hypertensive Drugs. Additionally, the government has been investing in healthcare, which has led to an increase in the availability of healthcare services. This has made it easier for people to access medication and manage their health conditions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.